About KangaBio
KangaBio, located in the Zhangjiang Biomedicine Valley of Shanghai, was founded in 2021 by Dr. Weidong Jiang. KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy.
Dr. Jiang previously co-founded Shanghai Henlius Biotech in 2009, a public company listed on Hong Kong stock exchange with five successfully launched biologics in the Chinese market as well as one in the European market. We are growing rapidly and recruiting global talent, centering our core values on speed, quality, globalization, and accountability.
Milestones
Key milestones from founding to growth
Angel Round $11M
Angel Round $11M
KGX101 US/AU Phase I
KGX101 US/AU Phase I
KGX103/KGX105 IND-enabling
Pre-A+ ~$15M
KGX103/KGX105 IND-enabling
Pre-A+ ~$15M
KGX105 P1
KGX103 IND Enabling
KGX105 P1
KGX103 IND Enabling
Corporate Culture
为患者提供更安全、更有效的创新药
To provide patients with safer and more effective innovative drugs
肿瘤免疫创新药的领跑者
To become a front runner in developing innovative immune-oncology drugs
核心价值观
Core Value & Culture
Management Team
Experienced management team
